


Accepted Manuscript

Addition of 10-day Decitabine to Fludarabine/TBI conditioning is feasible and induces tumor-associated antigen specific T-cell responses

Marjan Cruijisen, Willemijn Hobo, Walter J.F.M. van der Velden, Manita E.J. Bremmers, Rob Woestenenk, Brigitte Bär, J.H. Frederik Falkenburg, Michel Kester, Nicolaas P.M. Schaap, Joop Jansen, Nicole N.M. Blijlevens, Harry Dolstra, Gerwin Huls



PII: S1083-8791(16)00097-5

DOI: [10.1016/j.bbmt.2016.02.003](https://doi.org/10.1016/j.bbmt.2016.02.003)

Reference: YBBMT 54195

To appear in: *Biology of Blood and Marrow Transplantation*

Received Date: 26 October 2015

Accepted Date: 1 February 2016

Please cite this article as: Cruijisen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G, Addition of 10-day Decitabine to Fludarabine/TBI conditioning is feasible and induces tumor-associated antigen specific T-cell responses, *Biology of Blood and Marrow Transplantation* (2016), doi: 10.1016/j.bbmt.2016.02.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Addition of 10-day Decitabine to Fludarabine/TBI
conditioning is feasible and induces tumor-associated
antigen specific T-cell responses**

(short title: 10-day Decitabine/Fludarabine/TBI conditioning)

Marjan Cruijsen^{1,4}, Willemijn Hobo^{2,4}, Walter J.F.M. van der Velden¹, Manita E.J. Bremmers¹,
Rob Woestenenk², Brigitte Bär¹, J.H. Frederik Falkenburg³, Michel Kester³, Nicolaas P.M.
Schaap¹, Joop Jansen², Nicole N.M. Blijlevens¹, Harry Dolstra^{2,4}, Gerwin Huls^{1,2,4}

¹Department of Hematology, Radboudumc, Nijmegen, the Netherlands; ²Department of Laboratory
Medicine, Laboratory of Hematology, Radboudumc, Radboud Institute for Molecular Life Sciences,
Nijmegen, The Netherlands; ³Department of Hematology, LUMC, Leiden, the Netherlands; ⁴These
authors contributed equally.

Corresponding author:
Gerwin Huls, gerwin.huls@radboudumc.nl

PO Box 9101, 6500 HB , Nijmegen, Phone number: +31 24 8187384; Fax number: +31 24 3542080

Keywords: Decitabine, hypomethylating agents, NMA conditioning, HCT, poor risk AML/MDS

Text word count: 4024

Abstract word count: 255

Number of figures/tables: 7 (excluding 2 supplemental figures)

Number of references: 51

Download English Version:

<https://daneshyari.com/en/article/8431077>

Download Persian Version:

<https://daneshyari.com/article/8431077>

[Daneshyari.com](https://daneshyari.com)